Table 5.
APOE genotype effect on training response in selected variables for subjects who completed study
|
APOE Genotype |
|||||||
|---|---|---|---|---|---|---|---|
| ε2/ε3 |
ε3/ε3 |
ε4/ε3 |
|||||
| Variable | Baseline | Posttraining | Baseline | Posttraining | Baseline | Posttraining | APOE Genotype Effect, P Value |
| Weight, kg | 81.7 ± 17.2 | 80.8 ± 16.2 | 80.6 ± 16.9 | 79.3 ± 16.3 | 81.3 ± 21.0 | 79.9 ± 19.9 | 0.89 |
| BMI | 28.0 ± 5.0 | 27.7 ± 4.5 | 27.2 ± 4.7 | 26.8 ± 4.4 | 27.7 ± 5.5 | 27.3 ± 5.3 | 0.87 |
| WHR | 0.83 ± 0.010 | 0.82 ± 0.07 | 0.84 ± 0.09 | 0.84 ± 0.09 | 0.84 ± 0.08 | 0.83 ± 0.08 | 0.42 |
| %BF | 23.3 ± 4.9 | 22.4 ± 5.0 | 22.2 ± 6.5 | 21.3 ± 5.8 | 22.8 ± 6.8 | 21.7 ± 6.6 | 0.83 |
| V̇o2max, l/min | 2.49 ± 0.86 | 2.79 ± 0.96 | 2.62 ± 0.75 | 2.70 ± 0.80 | 2.57 ± 0.76 | 2.91 ± 0.84 | 0.001* |
| TC, mg/dl | 199.1 ± 38.6 | 196.2 ± 38.2 | 208.2 ± 37.3 | 206.3 ± 36.3 | 204.2 ± 37.0 | 205.0 ± 36.8 | 0.74 |
| TG, mg/dl | 142.1 ± 95.0 | 127.2 ± 79.5 | 144.1 ± 108.7 | 123.5 ± 78.3 | 128.1 ± 75.8 | 109.6 ± 59.4 | 0.86 |
| LDL-C, mg/dl | 120.7 ± 31.2 | 122.3 ± 30.0 | 129.9 ± 35.0 | 130.8 ± 29.0 | 132.6 ± 36.1 | 136.9 ± 35.3 | 0.70 |
| HDL-C, mg/dl | 49.9 ± 12.8 | 49.7 ± 11.6 | 49.4 ± 15.1 | 50.8 ± 14.3 | 46.0 ± 11.5 | 46.2 ± 10.3 | 0.45 |
| Glucose, mg/dl | 81.6 ± 6.2 | 80.9 ± 5.8 | 82.8 ± 7.1 | 80.2 ± 5.7 | 86.4 ± 10.3 | 83.1 ± 7.5 | 0.69 |
| Insulin, μU/ml | 6.1 ± 3.1 | 6.0 ± 3.6 | 5.9 ± 3.2 | 6.0 ± 3.2 | 9.0 ± 14.1 | 6.5 ± 4.7 | 0.18 |
| HLA, μmol FFA · ml−1 · h−1 | 19.6 ± 9.6 | 19.0 ± 8.8 | 16.4 ± 8.3 | 15.5 ± 6.8 | 18.7 ± 7.4 | 17.7 ± 8.2 | 0.66 |
| LPLA, μmol FFA · ml−1 · h−1 | 12.3 ± 3.1 | 13.1 ± 4.0 | 11.9 ± 3.9 | 11.4 ± 3.5 | 11.1 ± 3.8 | 12.4 ± 4.5 | 0.16 |
Data are means ± SD for n = 38 ε2/ε3, 42 ε3/ε3, and 35 ε4/ε3 subjects. APOE genotype effect is the change from pre- to posttraining. HLA, hepatic lipase activity; LPLA, lipoprotein lipase activity.
*
P < 0.001 indicates significant difference between ε3/ε3 and both ε4/ε3 and ε2/ε3.